The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study

Autor(es)

Forgerini, Marcela ; Urbano, Gustavo ; De Nadai, Tales Rubens ; Batah, Sabrina Setembre ; Fabro, Alexandre Todorovic ; Mastroianni, Patricia De Carvalho

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES; v. 26, p. 13-pg., 2023-01-30.

Resumo

Purpose: To investigate whether interindividual variability in the CYP2C9 (*2 and *3 alleles) and VKORC1 (rs9923231) genes is associated with increased risk of upper gastrointestinal bleeding (UGIB) in users of non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (LDA).Methods: A full case-control study including 200 cases of patients diagnosed with UGIB and 706 controls was conducted in a Brazilian hospital complex. To perform an analysis of NSAIDs dose-effect, the defined daily dose (DDD) for NSAIDs was calculated in the 7-day etiologic window preceding the data index. Three categories of DDD, considering the genotypes of the genetic variants, were established: non-users of NSAIDs (DDD = 0), DDD & LE;0.5, and DDD > 0.5. Genetic variants and LDA or NSAIDs use synergism was estimated through Synergism Index (SI) and Relative Excess Risk Due To Interaction (RERI).Results: For DDDs of NSAIDs upward of 0.50, a risk of UGIB was identified in carriers of the *3 allele (OR: 15,650, 95% CI: 1.41-174.10) and in carriers of the variant homozygous genotype (TT) of rs9923231 (OR: 38,850, 95% CI: 2.70-556.00). In LDA users, the risk of UGIB was observed to be similar between carriers of the wild type homozygous genotype and carriers of the variant alleles for the CYP2C9 and VKORC1 genes. No synergism was identified.Conclusion: Our findings suggest an increased risk of UGIB in carriers of the variant allele of rs9923231 and in carriers of the *3 allele associated with doses of NSAIDs greater than 0.5. Hence, the assessment of these variants might reduce the incidence of NSAIDs-related UGIB and contribute to the safety of the NSAIDs user. (AU)

• Processo FAPESP: 18/07501-9 - Determinantes genéticos da hemorragia gastrointestinal associada ao uso do ácido acetilsalicílico como agente antiplaquetário: um estudo caso-controle
• Beneficiário: Marcela Forgerini
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 17/24193-3 - Determinantes genéticos da hemorragia gastrointestinal associada ao uso de ácido acetilsalicílico como agente antiplaquetário: um estudo de caso-controle
• Beneficiário: Patricia de Carvalho Mastroianni
• Modalidade de apoio: Auxílio à Pesquisa - Regular